Using MRI to predict tumor infiltration in soft tissue and bone cancers
Development of a Radiomics Model With 3T Multiparametric MR to Predict the Occurence of a Perilesional Infiltration of Muscoskeletal Tumor During the Pre- Surgery Planning
This study is testing if special MRI scans can help doctors better identify tumor spread in patients suspected of having soft tissue sarcoma or bone cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 122 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06774729 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the feasibility and clinical utility of radiomics in diagnosing peri-lesion tumor infiltration in patients suspected of having soft tissue sarcoma or bone cancer. Participants will undergo MRI scans as part of their routine medical care, with their data being recorded and analyzed anonymously. The study seeks to determine the accuracy of radiomics in identifying true positive and negative diagnoses among participants. By leveraging advanced imaging techniques, the study hopes to enhance diagnostic capabilities for these serious conditions.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are suspected of having soft tissue sarcoma or bone cancer and are indicated for surgical treatment.
Not a fit: Patients with a history of cancer in the last 5 years or those with serious conditions that contraindicate MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of diagnosing tumor infiltration, leading to better treatment planning for patients with soft tissue sarcoma and bone cancer.
How similar studies have performed: While the use of radiomics in oncology is an emerging field, similar studies have shown promising results in enhancing diagnostic accuracy for various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age over 18 * suspect of soft tissue sarcoma with a indication for surgical treatment * suspect of bone cancer tumor with a indication for surgical treatment * To give informed consent Exclusion Criteria: * simultaneous cancer or history of cancer in the last 5 years * acute or chronic serious conditions that could * contraindication to conduct a Contrast-enhanced magnetic resonance imaging (MRI) such as: * renal failure without dialysis * history of allergy to a paramagnetic contrast agent * claustrophobia * symptomatic epilepsy or history of epilepsy * cardiac pacemaker * infusion pump, prosthesis or any implant not compatible with MRI * pregnancy
Where this trial is running
Bologna
- IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy (Recruiting)
Study contacts
- Study coordinator: Vincenzo Lucidi, MD
- Email: vincenzo.lucidi@aosp.bo.it
- Phone: +39 3385246923
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.